Stable BF <sub>2</sub> Boracycles as Versatile Reagents for Selective <i>Ortho</i> C–H Functionalization
Abstract
Abstract The development of new boron reagents continues to play a crucial role in advancing modern organic synthesis, particularly in C–H functionalization and cross‐coupling reactions. Herein, we report a metal‐free, robust, and scalable multigram protocol for the synthesis of stable BF 2 boracycles that require no column chromatography, providing a practical and efficient route to access this valuable boron species. The BF 2 boracycles exhibit enhanced stability and reactivity, making them highly versatile intermediates for late‐stage diversification. They undergo ipso ‐substitution to afford a wide array of derivatives, including halogenated (e.g., radioiodinated), hydroxylated, and azidated products. Furthermore, they display excellent reactivity in Suzuki–Miyaura cross‐coupling reactions, enabling both C(sp 2 )─C(sp 2 ) and C(sp 2 )─C(sp 3 ) bond formation. These results underscore the utility of BF 2 boracycles as powerful tools for selective functionalization in pharmaceutical synthesis and beyond. Our work represents a significant advancement in organoboron chemistry, offering both a streamlined synthetic approach and broad applicability for complex molecule construction.
Article Details
Authors (12)
Ganesh H. Shinde
Department of Chemistry and Molecular Biology University of Gothenburg Gothenburg Sweden SE‐41296
Jonatan Babiker
Department of Chemistry and Molecular Biology University of Gothenburg Gothenburg Sweden SE‐41296
Michelle Mebrahtu
Department of Chemistry and Molecular Biology University of Gothenburg Gothenburg Sweden SE‐41296
Anaïs Prigent
Université de Caen Normandie CERMN UR 4258 Caen 14000 France
Gauthier Foucras
Université de Caen Normandie CERMN UR 4258 Caen 14000 France
Yogesh N. Aher
Department of Chemistry and Molecular Biology University of Gothenburg Gothenburg Sweden SE‐41296
Francoise M. Amombo Noa
Department of Chemistry and Chemical Engineering Chalmers University of Technology Gothenburg Sweden SE‐41296
Magnus J. Johansson
Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, SE-43183 Mölndal, Sweden
Janez Košmrlj
Faculty of Chemistry and Chemical Technology University of Ljubljana Večna pot 113 Ljubljana 1000 Slovenia
Ross D. Jansen‐van Vuuren
Faculty of Chemistry and Chemical Technology University of Ljubljana Večna pot 113 Ljubljana 1000 Slovenia
Thomas Cailly
Université de Caen Normandie CERMN UR 4258 Caen 14000 France
Henrik Sundén
Department of Chemistry and Molecular Biology University of Gothenburg Gothenburg Sweden SE‐41296